Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman
© Gurzu et al.; licensee BioMed Central Ltd. 2013
Received: 1 May 2013
Accepted: 26 August 2013
Published: 16 September 2013
A 36-year-old female was hospitalized with symptoms suggesting intestinal occlusion. She was diagnosed with adenocarcinoma of the ampulla of Vater (pT4N0 stage) and underwent cephalic duodenopancreatectomy 8 months ago. Five cycles of postoperative chemotherapy were administrated using capecitabine and oxaliplatin (CAPOX or XELOX), the last one being completed 1 month ago. During the present hospitalization, because of normal computed tomography and ultrasound abdominal examination, rehydration and antibiotherapy were administrated. However, 4 days after hospital admission, the patient died. At autopsy and histological examination, we found a severe myocardial sclerosis with large scarring areas, severe steatohepatitis, chronic pancreatitis with large fibrotic areas, and acute enteritis. Alcohol consumption was denied. The patient died due to associated heart, liver and pancreatic failure. This multiorgan toxicity and death following CAPOX regimen had not yet been reported in the literature.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/6472150549833105
KeywordsCapecitabine Oxaliplatin Cardiotoxicity Chronic pancreatitis Steatohepatitis Enteritis Multiorgan toxicity Myocardial fibrosis Lethal Pericarditis
In advanced gastrointestinal (GI) cancers, an association between cytotoxic drugs and biological agents is usually used. The biological agents such as bevacizumab, cetuximab, and panitumumab seem to be well tolerated and exhibit promising results, but their cost-effectiveness has been seriously evaluated in the literature. Bevacizumab, an antiangiogenic drug, was approved by the Food and Drug Administration (FDA) in 2004 for the treatment of colorectal carcinoma. Cetuximab and panitumumab, the anti-EGFR (epidermal growth factor) agents, can also be used in case of GI tumors that do not display K-ras mutation. However, these agents cannot be used alone but only associated with classical chemotherapeutics, and have been approved only for metastatic cases, with the adjuvant protocol for locally advanced cancer being questionable.
In most of the GI locally advanced or metastatic tumors, cytotoxic drugs such as irinotecan, oxaliplatin, 5-fluorouracil (5-FU), and capecitabine are used as first-line therapy[1, 2]. Oxaliplatin was approved by the FDA in 2002 for the treatment of Stage III/IV (Dukes’ C/D) colorectal carcinoma, but it is also used in other adenocarcinomas of the GI tract. Depending on the patient’s functional status and comorbidities, different combination regimens are used, such as FOLFIRI (5-FU, leucovorin [folinic acid], irinotecan), FOLFOX (5-FU, leucovorin [folinic acid], oxaliplatin), and GEMOX (gemcitabine, oxaliplatin); in addition, monotherapy treatments are also utilized (5-FU, gemcitabine, capecitabine)[1–3]. As some clinical trials revealed significant cardiotoxicity in case of intravenous 5-FU, when compared with oral fluoropyrimidine also known as capecitabine, and similar or superior efficacy in case of capecitabine, the oral administration of capecitabine is preferred in association with oxaliplatin (XELOX or CAPOX)[2–5].
In locally advanced cases, at least two problems should be taken into account. On the one hand, the predictive criteria are not well defined, with the microsatellite status or immunostaining being more valuable as prognostic than predictive factors. On the other hand, despite the benefits of adjuvant therapy, its dose-dependent increased toxicity and costs should also be taken into account to select patients who are likely to benefit from them. In this study, we present a multiorgan fatal chemotherapy toxicity, in a 36-year-old female suffering from locally advanced adenocarcinoma of the ampulla of Vater. In addition, with regard to the rarity of this lesion, a review of the relevant literature regarding chemoterapy-induced toxicity has been carried out.
A 36-year-old cachectic female (body weight was 41.2 kg and height was 1.62 m), previously diagnosed with adenocarcinoma of the ampulla of Vater that invades the pancreas (pT4N0 stage), which was surgically removed (cephalic duodenopancreatectomy, radical surgery) 8 months ago, was admitted to our hospital with pale skin, scleral jaundice, sudden onset of severe abdominal pain and cramping, vomiting, diarrhea, and subfebrility. No alcohol, tobacco, or other drug use was declared. Before and after surgery and also before adjuvant therapy, no comorbidities were diagnosed, and the general status was carefully assessed without modification. Two months following surgery, she underwent five chemotherapy cycles with a combined regimen that included oral capecitabine and intravenous oxaliplatin (CAPOX or XELOX). CAPOX regimen comprised administration of 150 mg/m2 of oxaliplatin (diluted in a 5% glucose solution) intravenously over 120 min on Day 1, and then 1250 mg/m2 of oral capecitabine administered twice daily from Days 1 to 14, followed by 1-week drug holiday, in a 21-day cycle. The last (fifth) cycle was stopped 1 month before the present admission. The reason for choosing this aggressive regimen was the patients’ age and good pre-chemotherapy general status. There were no significant acute toxicity-related disorders, except slight diarrhea and vomiting, either of which recurred before this episode.
During the present admission, on physical examination, when palpating the abdomen, generalized abdominal tenderness with voluntary guarding was observed, with hypoactive bowel sounds. Considering her symptoms that suggested a tumor relapse, we decided to perform an emergency GI endoscopy that did not evidence tumor relapse or intestinal obstruction. The abdominal-computed tomography and ultrasound were normal. Her serology showed slight anemia (hemoglobin: 10 g/dl, hematocrit: 40%), thrombocytopenia (114,000 platelets/μl), leukocytosis (86.8% neutrophils and 11.5% lymphocytes), and elevated levels of amylase (147 U/L), total bilirubin (6.26 mg/dl), transaminases (aspartate transaminase [AST]: 56 U/L and alanine transaminase [ALT]: 40 U/L), and lactate dehydrogenase (484 U/L). Her glycemia was in normal limits (78 mg/dl). Electrocardiogram showed a slightly sinusal tachycardia and T-wave inversion. Adapted diet, bowel rest, antibiotherapy, and intravenous hydration were administrated, but the patient died 4 days after admission.
A particular histopathological aspect was also observed in the myocardium. Severe diffuse myocardial fibrosis was present in both right and left ventricles, in subendocardial and subpericardial areas (Figure 2). No coronarosclerosis or myocardium hypertrophy was evidenced. The heart weighted 365 g. Her cardiac function was normal before chemotherapy.
Based on the macro- and microscopic features, it was decided that the death was caused by multiorgan failure syndrome, with the main lesion being the chemotherapy-induced cardiotoxicity. The patient’s age, absence of coronarosclerosis or myocardium hypertrophy, and the associated-hepatic and pancreatic lesions proved that the myocardial disorders had toxic and non-ischemic etiology.
Adenocarcinomas of the ampulla of Vater are very rare malignant tumors of the GI tract. They are usually diagnosed in locally advanced or metastatic stages. Being rare tumors, the optimal first-line therapy has not yet been elucidated. One of the commonest first-line chemotherapeutics association is capecitabine in combination with oxaliplatin (CAPOX or XELOX).
Capecitabine is a pro-drug of the cytotoxic agent 5-FU which can be orally administrated and can release FU directly at the tumor site due to increased activity of thymidine phosphorylase in tumor cells, when compared with normal healthy ones, and most of the researchers admit that it presents a favorable side-effect profile[5, 7]. However, some toxic effects have been reported such as hand-foot syndrome or palmar-plantar erythrodysesthesia (painful fingers and toes), diarrhea, nausea, vomiting, and mucositis[4, 5, 8]. In about 60 studies reported to date, cardiotoxicity was infrequently observed, occurring in 1-18% of the cases, being displayed as angina (70%), arrhythmia (10%), myocardial infarction (10%), or cardiogenic shock (10%), without remission after dose reduction or additional medical prophylaxis[9, 10]. About 11% of the patients with capecitabine-associated cardiotoxicity were reported to have died. To date, about 25 cases with capecitabine-related hypertriglyceridemia have been reported[5, 8], and three of them also presented capecitabine-induced acute necrotizing pancreatitis that required interruption of capecitabine therapy[5, 7, 8, 11]. The pathogenesis of pancreatitis is not well elucidated, and some researchers have mentioned that capecitabine may reduce the activity of lipoprotein lipase and hepatic triglyceride lipase[5, 8, 12]. Pancreatitis can also be caused by surgery or the tumor location, such as in the reported case. However, no signs of pancreatitis were detected in our patient before this episode. It has also been suggested that the atherosclerotic risk could increase in patients treated with capecitabine over a 6-month period; however, adjuvant administration of fenofibrate could normalize the serum level of triglycerides. In the present case, the patient had chronic pancreatitis with large fibrotic areas and severe atrophy of the pancreatic parenchyma, without atherosclerosis, after five chemotherapy cycles of capecitabine-based regimen.
Oxaliplatin is a third-generation platinum-based alkylating agent that inhibits DNA synthesis in cancer cells. Its side effects mainly include sensory peripheral neuropathy, followed by fatigue, stomatitis, nausea, vomiting, diarrhea, pulmonary fibrosis, gastrointestinal and liver toxicity, ototoxicity, and nephrotoxicity[3, 4, 13]. The main hepatotoxic features are steatohepatitis, steatosis, and vascular changes displayed as fibrosis of sinusoids as well as central veins and necrosis of the central hepatocytes (sinusoidal obstruction syndrome). Steatohepatitis without vascular changes was evidenced in our case. Hepatotoxicity seems to be particularly present after more than six cycles of systemic chemotherapy, probably due to increased oxidative stress and direct effect of endotoxins; however, it could rather be a postoperative morbid effect and may not have led to the patient’s death. Hepatotoxicity could be prevented through supplementation of AdoMet (S-adenosylmethionine) in patients treated with oxaliplatin-based regimen, probably by increasing the activity of DNA methyltransferases. To date, only one study has reported the possible oxaliplatin-related acute pancreatitis in six GI tumors.
In case of CAPOX, the eligible patients should have a good performance status. According to Overman et al. (2009), patients with granulocytopenia (<1.500 granulocytes/mm3), thrombocytopenia (<100.000 platelets/mm3), and severe anemia (hemoglobin<10 mg/dl) are not eligible. Cardiac disease, brain metastases, renal function impairment (creatinine clearance <30 ml/min), and liver failure (total bilirubin>1.5 mg/dl, albumin>2.5 mg/dl, and elevated levels of transaminases) are also exclusion criteria, although some researchers have proved that the combination of oxaliplatin and capecitabine could also be tolerated in patients with hyperbilirubinemia and hepatic dysfunctions, respectively.
In one of the largest prospective phase II clinical studies performed with CAPOX in cases of adenocarcinomas of the small bowel and ampulla of Vater, the following related toxicities were observed: fatigue, peripheral neuropathy, nausea, diarrhea, hand-foot syndrome, and hematologic disorders such as neutropenia, anemia, and thrombocytopenia. The researchers proved that CAPOX regimen was well tolerated and highly effective, with an overall response rate of 50% and no treatment-related deaths. Other rare lesions, such as cerebral infarction, stomatitis, hypomagnesemia, hyperbilirubinemia, hyperglycemia, and hypocalcemia were also reported to be associated with combination regimen of capecitabine and oxaliplatin[8, 16]. To our knowledge, no cases with CAPOX-induced chronic pancreatitis have been reported till date, and in only three cases, ileitis occurred in patients with metastatic colorectal carcinomas treated with oxaliplatin, capecitabine, and bevacizumab.
It must be noted that in the case presented in this study, the CAPOX regimen was highly effective, without relapses and/or metastases; however, fatal signs of toxicity occurred 1 month after completion of the five cycles. Even in young patients with a good performance status, chemotherapy-induced cardiotoxicity, GI, and liver toxicity, as well as pancreatitis should be taken in account.
Although chemotherapeutics toxicity is a well-known adverse drug reaction, any toxicity should be carefully approached and widely disseminated, to increase general knowledge. The particularity of this case was the multiorgan toxicity that occurred in a young female with a pT4N0-staged carcinoma of the ampulla of Vater treated with questionable maximum dose of XELOX regimen. These fatal toxic associations highlight the necessity of establishing new standardized predictive criteria for postoperative oncological management of non-metastatic locally advanced cancers of the intestine and colon segments, according to gender and functional status, which will be applicable in clinical practice.
Written informed consent was obtained from the patient’s relatives for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- CAPOX or XELOX:
Therapetic regimen that associates oral administration of capecitabine and oxaliplatin
Epidermal growth factor
Food and Drug Administration
Therapetic regimen that associates 5-fluorouracil (5-FU) leucovorin [folinic acid], and irinotecan
Therapetic regimen that associates 5-FU, leucovorin, and oxaliplatin
Therapetic regimen that associates gemcitabine and oxaliplatin
The English-language manuscript was polished by SPI Global Professional Editing Service.
- Dekanic A, Dintinjan RD, Budisavljevic I, Pecanic S, Butorac MZ, Jonic N: Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol. 2011, 6: 108-10.1186/1746-1596-6-108.PubMed CentralView ArticlePubMedGoogle Scholar
- Cartwright TH: Treatment decision after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer. 2012, 11: 155-166. 10.1016/j.clcc.2011.11.001.View ArticlePubMedGoogle Scholar
- Butt W, Saadati H, Saif MW: Oxaliplatin-induced pancreatitis: a case series. Anticancer Res. 2010, 30: 5113-5116.PubMedGoogle Scholar
- Overman MJ, Varadhachary GR, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA: Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowell and ampulla of Vater. J Clin Oncol. 2009, 27: 2598-2603. 10.1200/JCO.2008.19.7145.View ArticlePubMedGoogle Scholar
- Chan HY, Ng CM, Tiu SC, Chan AOK, Shek CC: Hypertrigliceridaemia-induced pancreatitis: a contributory role of capecitabine?. Hong Kong Med J. 2012, 18: 526-529.PubMedGoogle Scholar
- Wangefjord S, Brandstedt J, Lindquist KE, Nodin B, Jirstrom K, Eberhard J: Associations of beta-catenin alterations and MSI screening status with expression of key cell ceycle regulating proteins and survival form colorectal cancer. Diagn Pathol. 2013, 8: 10-10.1186/1746-1596-8-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Yucel H, Warmerdam LV: Capecitabine-induced pancreatitis. J Oncol Pharm Pract. 2010, 16: 133-134. 10.1177/1078155209344650.View ArticlePubMedGoogle Scholar
- Michie CO, Sakala M, Rivans I, Strachan MWJ, Clive S: The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer. 2010, 103: 617-621. 10.1038/sj.bjc.6605807.PubMed CentralView ArticlePubMedGoogle Scholar
- Y-Hassan S, Tornvall P, Tornerud M, Henareh L: Capecitabine caused cardiogenic shock through induction of global takotsubo syndrome. Cardiovasc Revasc Med. 2013, 14: 57-61.View ArticlePubMedGoogle Scholar
- Manojlovic N, Babic D, Stojanovic S, Filipovic I, Radoje D: Capecitabine cardiotoxicity - case reports and literature review. Hepatogastroenterology. 2008, 55: 1249-1256.PubMedGoogle Scholar
- Jones KL, Valero V: Capecitabine-induced pancreatitis. Pharmacotherapy. 2003, 23: 1076-1078. 10.1592/phco.23.8.1076.32870.View ArticlePubMedGoogle Scholar
- Stathopoulos GP, Koutantos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G: Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects. Anticancer Res. 2007, 27: 1653-1656.PubMedGoogle Scholar
- Pessaux P: Chemotherapy’s hepatotoxicity: what is the impact on surgery?. J Chir (Paris). 2010, 147 (Suppl 1): S7-S11.Google Scholar
- Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G: The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012, 20: 135-139. 10.1007/s00520-010-1078-4.View ArticlePubMedGoogle Scholar
- Luo S, Zhang X, Yu M, Yan H, Liu H, Wilson JH, Huang G: Folic acid acts through DNA methyltransferases to induce the differentiation of neural stem cells into neurons. Cell Biochem Biophys. 2013, 66: 559-566. 10.1007/s12013-012-9503-6.View ArticlePubMedGoogle Scholar
- Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O’Neill BH: Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res. 2011, 4: 78-83.PubMed CentralPubMedGoogle Scholar
- Bouma G, Imholz AL: Ileitis following capecitabine use. Ned Tijdschr Geneeskd. 2011, 155: A3064-PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.